BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38584178)

  • 21. A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer.
    Salminen L; Nadeem N; Jain S; Grènman S; Carpén O; Hietanen S; Oksa S; Lamminmäki U; Pettersson K; Gidwani K; Huhtinen K; Hynninen J
    Gynecol Oncol; 2020 Mar; 156(3):689-694. PubMed ID: 31889528
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
    Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
    Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The value of CA 125 and CA72-4 in management of patients with epithelial ovarian cancer.
    Fayed ST; Ahmad SM; Kassim SK; Khalifa A
    Dis Markers; 1998 Nov; 14(3):155-60. PubMed ID: 10427474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling.
    Tiss A; Timms JF; Smith C; Devetyarov D; Gentry-Maharaj A; Camuzeaux S; Burford B; Nouretdinov I; Ford J; Luo Z; Jacobs I; Menon U; Gammerman A; Cramer R
    Int J Gynecol Cancer; 2010 Dec; 20(9):1518-24. PubMed ID: 21370595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CAM26, CAM29 and mucin-like carcinoma associated antigen in epithelial ovarian cancer.
    Ferdeghini M; Gadducci A; dell'Hoste M; Prontera C; Ceccarini T; Rispoli G; Bianchi R; Fioretti P
    Eur J Gynaecol Oncol; 1990; 11(5):395-401. PubMed ID: 1965803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic accuracy of haptoglobin within ovarian cyst fluid as a potential point-of-care test for epithelial ovarian cancer: an observational study.
    Mahyuddin AP; Liu L; Zhao C; Kothandaraman N; Salto-Tellez M; Pang B; Lim D; Annalamai L; Chan J; Lim T; Biswas A; Rice G; Razvi K; Choolani M
    BJOG; 2018 Mar; 125(4):421-431. PubMed ID: 28755436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The clinical value of the combined detection of sEGFR, CA125 and HE4 for epithelial ovarian cancer diagnosis.
    Li Y; Wang ZC; Luo L; Mu CY; Xu J; Feng Q; Li SB; Gu B; Ma P; Lan T
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):604-610. PubMed ID: 32016961
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spectrally and Spatially Multiplexed Serological Array-in-Well Assay Utilizing Two-Color Upconversion Luminescence Imaging.
    Kale V; Päkkilä H; Vainio J; Ahomaa A; Sirkka N; Lyytikäinen A; Talha SM; Kutsaya A; Waris M; Julkunen I; Soukka T
    Anal Chem; 2016 Apr; 88(8):4470-7. PubMed ID: 26996057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of Seven Clinical Tumor Markers in Diagnosis of Non-Small-Cell Lung Cancer.
    Chen ZQ; Huang LS; Zhu B
    Dis Markers; 2018; 2018():9845123. PubMed ID: 30647803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of glyco-mucin profiles improves specificity of MUC16 and MUC1 biomarkers in ovarian serous tumours.
    Ricardo S; Marcos-Silva L; Pereira D; Pinto R; Almeida R; Söderberg O; Mandel U; Clausen H; Felix A; Lunet N; David L
    Mol Oncol; 2015 Feb; 9(2):503-12. PubMed ID: 25454345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Establishment of an HE4-CLIA Method and the Combined Analysis of HE4 and CA125 in Ovarian Cancer.
    Zhang Q; Wang CR; Yu JP; Ma Q; Xu WW
    J Clin Lab Anal; 2016 Sep; 30(5):709-18. PubMed ID: 26990679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Luminescence energy transfer detection of PSA in red region based on Mn2+-enhanced NaYF4:Yb, Er upconversion nanorods.
    Zhang J; Wang S; Gao N; Feng D; Wang L; Chen H
    Biosens Bioelectron; 2015 Oct; 72():282-7. PubMed ID: 25996781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mucin 13 (MUC13) as a candidate biomarker for ovarian cancer detection: potential to complement CA125 in detecting non-serous subtypes.
    Ren AH; Filippou PS; Soosaipillai A; Dimitrakopoulos L; Korbakis D; Leung F; Kulasingam V; Bernardini MQ; Diamandis EP
    Clin Chem Lab Med; 2023 Feb; 61(3):464-472. PubMed ID: 36380677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression and significance of ER, PR, VEGF, CA15-3, CA125 and CEA in judging the prognosis of breast cancer.
    Zhang SJ; Hu Y; Qian HL; Jiao SC; Liu ZF; Tao HT; Han L
    Asian Pac J Cancer Prev; 2013; 14(6):3937-40. PubMed ID: 23886210
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the importance of the serum levels of CA-125, CA15-3, CA-19-9, carcinoembryonic antigen and alpha fetoprotein for distinguishing benign and malignant adnexal masses and contribution of different test combinations to diagnostic accuracy.
    Bozkurt M; Yumru AE; Aral I
    Eur J Gynaecol Oncol; 2013; 34(6):540-4. PubMed ID: 24601047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validation of LRG1 as a potential biomarker for detection of epithelial ovarian cancer by a blinded study.
    Wu J; Yin H; Zhu J; Buckanovich RJ; Thorpe JD; Dai J; Urban N; Lubman DM
    PLoS One; 2015; 10(3):e0121112. PubMed ID: 25799488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of mucin-specific monoclonal antibodies and lectins in the detection of tumor-associated serum markers in gynecological cancer.
    Devine PL; McGuckin MA; Ramm LE; Harada H; Ward BG
    Cancer Biochem Biophys; 1993 Sep; 13(4):221-38. PubMed ID: 8521372
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Highly Sensitive and Selective Photoelectrochemical Aptasensor for Cancer Biomarker CA125 Based on AuNPs/GaN Schottky Junction.
    Hu D; Liang H; Wang X; Luo F; Qiu B; Lin Z; Wang J
    Anal Chem; 2020 Jul; 92(14):10114-10120. PubMed ID: 32580543
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
    Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
    Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a multi-marker model combining HE4, CA125, progesterone, and estradiol for distinguishing benign from malignant pelvic masses in postmenopausal women.
    Zhang P; Wang C; Cheng L; Zhang P; Guo L; Liu W; Zhang Z; Huang Y; Ou Q; Wen X; Tian Y
    Tumour Biol; 2016 Feb; 37(2):2183-91. PubMed ID: 26349751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.